AAO 2023: Improving Quality of Life in Patients With Diabetic Macular Edema

Sunir J. Garg, MD

November 20, 2023

Sunir J. Garg, MD, reflects on highlights regarding diabetic macular edema (DME) from the 2023 American Academy of Ophthalmology Annual Meeting. As Dr Garg notes, current medications for DME require frequent visits, affecting patients' lives significantly due to associated complications with retinopathy, kidney disease, and cardiovascular issues. However, newly FDA-approved treatments exhibit prolonged efficacy and improve macular anatomy more effectively than previous agents.

Dr Garg shares a transformative experience with a patient benefiting from these newer medications, the use of which reduced treatment frequency, resulting in sustained visual acuity and improved quality of life for the patient.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: AAO 2023: Improving Quality of Life in Patients With Diabetic Macular Edema - Medscape - Nov 20, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.